Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.

International journal of clinical pharmacy|2023|Cao M et al.|13 citations

BACKGROUND: There are increasing data on the potential risk of pancreatic carcinoma associated with glucagon-like peptide 1 receptor agonists (GLP-1RAs). AIM: The study aimed to determine whether GLP-1RAs are associated with increased detection of pa…

PMID: 36977858

Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.

Alimentary pharmacology & therapeutics|2023|Romero-Gómez M et al.|23 citations

BACKGROUND: Non-alcoholic steatohepatitis (NASH) can adversely affect health-related quality of life (HRQoL). AIMS: This double-blind, placebo-controlled, phase 2 trial aimed to report the effects of the glucagon-like peptide-1 receptor agonist, sema…

Randomized Controlled Trial

PMID: 37328931

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD.

Current issues in molecular biology|2023|Petrovic A et al.|30 citations

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to improve glucose and lipid homeostasis, promote weight loss, and reduce cardiovascular risk factors. They are a promising therapeutic option for non-alcoholic fatty liver disease…

ReviewAnimal StudyIn Vitro

PMID: 37367037

The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways.

Cell biochemistry and function|2023|Atef M et al.|12 citations

The cardiotoxic effect of chemotherapeutic agents as cisplatin has become a major issue recently. Interference with mitochondrial dynamics, biogenesis, redox status, and apoptosis are the most possible underlying mechanisms. Semaglutide is a human gl…

Animal Study

PMID: 37051656

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.

Advances in therapy|2023|Wolffenbuttel B et al.|18 citations

INTRODUCTION: SURE Netherlands (NCT03929679) evaluated the use of once-weekly (OW) semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), in routine clinical care for individuals with type 2 diabetes (T2D). METHODS: Adults (age ≥ 18 years…

Observational

PMID: 36542260

Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.

Clinical rheumatology|2023|Posso-Osorio I et al.|9 citations

Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated report…

ReviewCase Report

PMID: 37199890

Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.

Pharmaceuticals (Basel, Switzerland)|2023|Hachuła M et al.|4 citations

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have MASLD, and, at the same time, the presence of MASLD increases the risk…

PMID: 37764998

Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.

Aesthetic surgery journal|2023|Han S et al.|104 citations

Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of diabetes that have recently gained FDA approval for medical management of obesity. The off-label use of Ozempic (Novo Nordisk, Bagsværd, Denmark), the brand name of t…

PMID: 37402640

Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.

Diabetes, obesity & metabolism|2023|von Arx L et al.|5 citations

AIMS: To determine the extent of therapeutic inertia related to the weekly injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes (T2D) in the United Kingdom. MATERIALS AND METHODS: Adults wi…

PMID: 36692268

Linking self-perceived cognitive functioning questionnaires using item response theory: The subjective cognitive decline initiative.

Neuropsychology|2023|Rabin L et al.|17 citations

OBJECTIVE: Self-perceived cognitive functioning, considered highly relevant in the context of aging and dementia, is assessed in numerous ways-hindering the comparison of findings across studies and settings. Therefore, the present study aimed to lin…

PMID: 37276136

Once-Weekly Semaglutide in Adolescents with Obesity.

The New England journal of medicine|2023|Malozowski S

PMID: 36947475

As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.

JAMA|2023|Suran M|43 citations

PMID: 37099334

Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.

Facial plastic surgery : FPS|2023|Hansen M, Krogh Pedersen K, Jia T|4 citations

PMID: 38604245

Acute Pancreatitis in a Patient Taking Semaglutide.

Cureus|2023|Patel F et al.|16 citations

The Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in managing type 2 diabetes by stimulating insulin secretion a…

Case Report

PMID: 37731423

Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice.

Diabetes, obesity & metabolism|2023|de Heide L et al.|10 citations

AIM: To evaluate medical and surgical treatment of postbariatric hypoglycaemia (PBH) in daily practice. MATERIALS AND METHODS: Retrospective data were extracted from medical records from four hospitals. PBH was defined by neuroglycopenic symptoms tog…

PMID: 36377811

Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Obesity (Silver Spring, Md.)|2023|Wilkinson L et al.|13 citations

OBJECTIVE: In the Semaglutide Treatment Effect in People with obesity (STEP) trials, once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body weight and improved cardiometabolic parameters in adults with obesity (or overwe…

Randomized Controlled Trial

PMID: 37605636

Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review.

Expert opinion on pharmacotherapy|2023|De R et al.|3 citations

INTRODUCTION: Psychotropic medications, especially antipsychotics, have been consistently shown to cause weight gain in individuals with severe mental illness (SMI), a population inherently challenged by poor physical health. Consequently, compared t…

Review

PMID: 37653675

Ongoing challenges of off-label prescribing.

Australian prescriber|2023|Day R|17 citations

Off-label prescribing refers to prescribing that is not concordant with the indications, doses, routes of administration or patient groups included in the Australian approved product information. Off-label prescribing is common, especially for vulner…

Review

PMID: 38152320

A Case of Dulaglutide-Induced Vaginal Bleed.

Cureus|2023|Vaccaro C et al.|2 citations

Type 2 diabetes mellitus (T2DM) is a growing challenge across the globe. The disease process is amendable to lifestyle modifications in the early stages. If those changes fail to correct endocrine dysfunction, medical therapy is initiated. Initially,…